Retatrutide
Also known as: Triple GLP-1/GIP/Glucagon agonist, LY3437943
Classification
Pharmaceutical
Regulatory Status
Investigational drug
Overview
Triple receptor agonist targeting GLP-1, GIP, and glucagon receptors for metabolic effects
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Educational reference only. Not a therapeutic recommendation. Clinical studies ongoing.
Pathways
glucose-regulationappetite-regulationmetabolic
Benefits
weight lossblood sugar controlmetabolic health
Sources
- Eli Lilly clinical research
- Metabolic syndrome studies
Educational reference only — not medical advice.